ArticleJournal of clinical medicine2020

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Gabriel Rinnerthaler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.